Bellon Christine 4

What Happened
Christine Bellon, Chief Legal Officer of Beam Therapeutics (BEAM), was granted a derivative equity award consisting of 40,000 stock options on January 31, 2026. The Form 4 reports the award as 40,000 shares at $0.00 (derivative), meaning no cash was paid at grant and the award represents options/rights rather than immediately owned shares. This is a compensatory award rather than an open‑market purchase or sale.

Key Details

• Transaction date: 2026-01-31; Form 4 filed 2026-02-02.
• Transaction type/code: Award/Grant (A); reported as 40,000 derivative shares at $0.00.
• Reported dollar value on form: $0 (reflects grant reporting; intrinsic value not shown).
• Vesting: Footnote F1 — vests in equal monthly installments over the next 48 months, subject to continued service.
• Shares owned after transaction: Not disclosed in this filing.
• No indication of a 10b5-1 plan, tax withholding, or immediate sale in this filing.

Context
This is a standard equity compensation grant to an executive and does not represent an immediate purchase or sale of company stock. Because the options vest monthly over four years, they become exercisable gradually only if the executive remains employed. Such grants are common for retention and compensation; they do not by themselves signal a near‑term market action (e.g., immediate sale) by the insider.